8 October 2025
Macomics Announces Neurodegeneration and Neuroinflammation Applications of ENIGMAC Drug Discovery Platform
12 August 2024
Macomics Team Scores Gold and Raises Over £600 in its Hyper-Triathlon Challenge in aid of Founder Prof. Jeffrey Pollard’s Memorial Fund
19 June 2024
Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development
10 June 2024
Macomics Announces Appointment of Simon Dew as New Chief Business Officer
14 May 2024
Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration
11 April 2024
Macomics Unveils its Lead First-in-Class Anti-Pan-LILR Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
28 October 2023
Macomics included in PwC Future 50 list
19 October 2023
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
29 September 2023
Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB
3 May 2023
In Memoriam Jeffrey William Pollard – Macomics’ founder, director and advisor
17 April 2023
Macomics Presents its ENIGMAC™ Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR
23 March 2023
Macomics and Ono Pharmaceutical partner to discover and develop macrophage-targeting antibody therap
20 February 2023
Mapping out the discoveries of a new class of tumour-associated immune cells
22 November 2022
Macomics’ co-founder Professor Jeffrey Pollard celebrated in Highly Cited Researchers 2022
3 October 2022
Professor Jeffrey Pollard Macomics’ Co-founding Board Member and Chair of its SAB Elected to the Academia Europaea
12 September 2022
Macomics announces the appointment of Roche Executive, Dr Valérie Méresse Naegelen
5 September 2022
Macomics to present at upcoming conferences in September and October
18 July 2022
Macomics announces new hires as it expands its macrophage-based drug discovery and operations teams
12 May 2022
Macomics to present at upcoming conferences
24 January 2022
Macomics brings on five additional advisors with internationally renowned immunology and clinical oncology expertise
26 November 2021
Macomics’ Co-founder Professor Jeffrey Pollard honoured in Highly Cited Researchers 2021
15 November 2021
Macomics’ co-founder Dr Luca Cassetta honoured with Society for Immunotherapy of Cancer Award for Publication
1 October 2021
Macomics announces new hires that expands its macrophage-based drug discovery R&D Team
29 July 2021
Macomics secures £4.24 million expansion financing
8 July 2021
Dr. Krzystof Wicher, to Chair sessions at the European Drug Discovery Strategic Summit
1 July 2021
Macomics appoints leading cancer immunologists to its advisory panel
11 May 2021
Macomics welcomes Founder, Prof. Jeffrey W. Pollard’s review article in leading journal Immunity
16 March 2021
Macomics Senior Scientist, Dr. Martha Lopez-Yrigoyen to Chair sessions at 2021 Tumour myeloid Microenvironment Directed Therapeutics Summit
14 July 2020
Macomics secures £3.2 million seed funding
